$42.81
-6.21-12.67%
Last update: Nov 9, 4:44 PM
Hemab Therapeutics Holdings Inc
COAGNASDAQ
Hemab Therapeutics rose 25.9% from $34.00 to $42.81, ahead of the S&P 500's +4.4%. Its worst day was May 4 (−25.5%), and its low came Jun 12 at $24.98.
May 1, 2026 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Hemab Therapeutics shares fell 25.5%, while the S&P 500 fell 0.4%.
−25.5%, the year's worst day · S&P 500 −0.4%
EPS of $-23.98 was reported on $0.00 revenue.
−0.6% · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
Hemab Therapeutics closed at its lowest level of the year, 26.5% below where the year started.
−7.3% · S&P 500 +0.5%
Presentation Highlights and Details – The abstracts are now available through the ISTH conference websiteSutacimigSutacimig showed sustained prophylaxis in GT (meaningful reduction in ATBR and high-intensity treatment
+16.8%, the year's best day · S&P 500 −0.7%
EPS of $-0.80 missed the $-0.78 estimate on $0.00 revenue.
+3.7% · S&P 500 −0.3%
Where it ended: a close of $42.81 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $-0.51).
Nothing in the past 12 months.
All COAG dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for COAG and SPY from Benzinga historical bars. Not investment advice.
